Cyclo Therapeutics drug shows early positive results in NPC1 sub-study

Cyclo Therapeutics, through a collaboration with Rafael Holdings, reported preliminary findings from a Phase 3 sub-study of its investigational therapy Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 (NPC1). The open-label, single-arm trial assessed patients young…